Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"EdiGene","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"EdiGene"}]

EdiGene

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies

Details:

Under the partnership, EdiGene will work with the David Gamm Laboratory to evaluate the pharmacological property of LEAPER™ RNA employs short engineered ADAR-recruiting RNAs (arRNAs) base editing candidates targeting specific genetic diseases.

Lead Product(s): Short Engineered ADAR-recruiting RNAs

Therapeutic Area: Genetic Disease Product Name: arRNAs

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: University of Wisconsin–Madison

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 09, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY